Molecular imaging of psychiatric disorders has taken a few turns around the lab as a concept, and while some potential imaging methods, namely dopamine transport scanning, have shown some potential, the technique has not really taken off for psychiatric applications due to a mixed bag of results and a limited understanding of the pathophysiology.

First-order treatment of cancer typically involves chemo and/or radiation therapy and surgical intervention, but radionuclide therapies offer some advantages for select patients by delivering a very intense dose sequestered to affected tumor sites.

During the past five years, I have spent a considerable amount of time on the issue of supply of Tc-99m and its parent, Mo-99.

The first PET imaging study of its kind to show the viability of tumor angiogenesis imaging in humans with investigational Ga-68 NODAGA-Theranost has been conducted by researchers from the Theranostics Center for Molecular Radiotherapy and Molecular Imaging in Bad Berka, Germany, and other institutions including the National Cancer Institute and Advanced Imaging Projects based in Boca Raton, Fla. Molecular Imaging has obtained an exclusive sneak-peek at the study.

Watch a presentation on nanoconstructs in cancer theranostics from the Methodist Hospital Research Institute and Tel Aviv University (TAU) posted online from the recent Summer School on Nanomedicine and Innovation.

Hyperscan is debuting at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), held September 14 – 16 in San Francisco.  Mevion representatives will formally introduce Hyperscan at booth 728 in the exhibit hall.

In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast cancer than does conventional IHC-FISH pathology testing.

Makers of F-18 florbetapir (Amyvid) are bankrolling a lawsuit against the Centers for Medicare & Medicaid Services (CMS), which hampered coverage of amyloid imaging earlier this year as a means for ruling out Alzheimer’s disease. The lawsuit was filed in federal court by Lilly and others Sept. 5, according to this Wall Street Journal report.